K. Sobotta, MD

Articles by K. Sobotta, MD

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy

ByMichael Untch, MD, PhD,Franz Von Koch, MD,C. Crohns, MD,K. Sobotta, MD,Steffen Kahlert, MD,Gottfried E. Konecny, MD,H. Hepp, MD

May 1st 2001

Several attempts have been made to improve the survival rates of breast cancer patients. The benefit of adjuvant chemotherapy was clearly shown, but the absolute difference of 2% to 11% in overall survival, depending on the

Latest Updated Articles

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy
Published: May 1st 2001 | Updated:

K. Sobotta, MD

Articles by K. Sobotta, MD

Dose-Dense and Sequential Strategies in Adjuvant Breast Cancer Therapy

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Revumenib in R/R NPM1-Mutant AML

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC